MedTrace Logo

A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

NCT01712399 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 409

Last updated 2017-06-01

Study results available
· View outcomes & findings →

Summary

A clinical study to investigate the safety of mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumatoid arthritis, an inflammatory condition that affects the joints.

Conditions

Interventions

BIOLOGICAL

Mavrilimumab 100 mg

Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-28
Primary Completion
2015-12-30
Completion
2015-12-30

Countries

  • Argentina
  • Bulgaria
  • Chile
  • Colombia
  • Czechia
  • Estonia
  • Germany
  • Greece
  • Hungary
  • Israel
  • Mexico
  • Poland
  • Russia
  • Serbia
  • Slovakia
  • South Africa
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01712399 on ClinicalTrials.gov